A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk-Reference-Cited by-同舟云学术

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk

Published:2022-07-27 Issue:2 Volume:44 Page:446-453
ISSN:1671-4083
Container-title:Acta Pharmacologica Sinica
language:en
Short-container-title:Acta Pharmacol Sin

Author:

Zhang Hao,Gu Jie-mei,Chao Ai-jun,Cheng Qun,Teng Dong-hui,Yu Jin-ming,Wang Bing-wu,Huo Ya-nan,Mao Li,Zhang Qiu,Yang Hong,Yan Shi-gui,Zhang Ke-qin,Zhao Xue-ling,Lin Hua,Pei Yu,Yuan Zhong,Dai Ru-chun,He Liang,Chen Li,Su Yong-feng,Deng Zhong-liang,You Li,Ban Bo,Zhu Mei,Cao You-liang,Zhu Yi-kun,Li Zhi-jun,Zhang Zhi,Yi Cheng-qing,Lu Yi-bing,Wang Guang,Han Cui-cui,Wang Zhen-jiang,Li Xian-xing,Zhang Zhen-lin

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

https://www.nature.com/articles/s41401-022-00954-y.pdf

Reference21 articles.

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA. 2001;285:785–95.

2. Compston JE, McClung MR, Leslie WD. Osteoporosis. Lancet. 2019;393:364–76.

3. Wang Y, Tao Y, Hyman ME, Li J, Chen Y. Osteoporosis in China. Osteoporos Int. 2009;20:1651–62.

4. Gao C, Xu Y, Li L, Gu WQ, Yi CT, Zhu Q, et al. Prevalence of osteoporotic vertebral fracture among community-dwelling elderly in Shanghai. Chin Med J. 2019;132:1749–51.

5. Xia WB, He SL, Xu L, Liu AM, Jiang Y, Li M, et al. Rapidly increasing rates of hip fracture in Beijing, China. J Bone Min Res. 2012;27:125–9.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Siwu decoction exerts a phytoestrogenic osteoprotective effect on postmenopausal osteoporosis via the estrogen receptor/phosphatidylinositol 3-kinase/serine/threonine protein kinase pathway;Journal of Ethnopharmacology;2024-10

2. Efficacy and safety of candidate biosimilar CT-P41 versus reference denosumab: a double-blind, randomized, active-controlled, Phase 3 trial in postmenopausal women with osteoporosis;Osteoporosis International;2024-07-23

3. Randomized, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of the denosumab biosimilar MW031 in Chinese postmenopausal women with osteoporosis;Expert Opinion on Biological Therapy;2024-05-16

4. Age-related disease: Bones;Aging;2024

5. Denosumab vs placebo efficacy in bone mineral density, bone turnover markers, and function in osteopenic patients with lumbar degenerative diseases after lumbar fusion surgery: a randomized controlled trial;2023-02-20